Iberdomide
- Generic Name
- Iberdomide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Not yet recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Drug: IberdomideBiological: Belantamab MafodotinDrug: DexamethasoneProcedure: EchocardiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT06232044
- Locations
- 🇺🇸
Mary Greeley Medical Center, Ames, Iowa, United States
🇺🇸McFarland Clinic - Ames, Ames, Iowa, United States
🇺🇸McFarland Clinic - Boone, Boone, Iowa, United States
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: IberdomideProcedure: Patient MonitoringProcedure: Positron Emission TomographyProcedure: Skeletal Survey X-Ray
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT06179888
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath